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Abstract
Background: The positron-emitting radionuclide
89Zr (t1/2=3.17 days) was used to prepare
89Zr-radiolabeled trastuzumab
for use as a radiotracer for characterizing HER2/neu-positive breast tumors. In addition, pharmacodynamic studies on HER2/
neu expression levels in response to therapeutic doses of PU-H71 (a specific inhibitor of heat-shock protein 90 [Hsp90]) were
conducted.
Methodology/Principal Findings: Trastuzumab was functionalized with desferrioxamine B (DFO) and radiolabeled with
[
89Zr]Zr-oxalate at room temperature using modified literature methods. ImmunoPET and biodistribution experiments in
female, athymic nu/nu mice bearing sub-cutaneous BT-474 (HER2/neu positive) and/or MDA-MB-468 (HER2/neu negative)
tumor xenografts were conducted. The change in
89Zr-DFO-trastuzumab tissue uptake in response to high- and low-
specific-activity formulations and co-administration of PU-H71 was evaluated by biodistribution studies, Western blot
analysis and immunoPET.
89Zr-DFO-trastuzumab radiolabeling proceeded in high radiochemical yield and specific-activity
104.362.1 MBq/mg (2.8260.05 mCi/mg of mAb). In vitro assays demonstrated .99% radiochemical purity with an
immunoreactive fraction of 0.8760.07. In vivo biodistribution experiments revealed high specific BT-474 uptake after 24, 48
and 72 h (64.68613.06%ID/g; 71.71610.35%ID/g and 85.18611.10%ID/g, respectively) with retention of activity for over
120 h. Pre-treatment with PU-H71 was followed by biodistribution studies and immunoPET of
89Zr-DFO-trastuzumab.
Expression levels of HER2/neu were modulated during the first 24 and 48 h post-administration (29.7564.43%ID/g and
41.4263.64%ID/g, respectively). By 72 h radiotracer uptake (73.64612.17%ID/g) and Western blot analysis demonstrated
that HER2/neu expression recovered to baseline levels.
Conclusions/Significance: The results indicate that
89Zr-DFO-trastuzumab provides quantitative and highly-specific
delineation of HER2/neu positive tumors, and has potential to be used to measure the efficacy of long-term treatment with
Hsp90 inhibitors, like PU-H71, which display extended pharmacodynamic profiles.
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Introduction
In the era of molecular medicine, antibody-based agents offer
unparalleled potential as platforms for the development of target-
specific therapies.[1] Immunoconjugates are monoclonal anti-
bodies (mAbs) or antibody fragments functionalized with
cytotoxic and/or diagnostic payloads. Increasing availability of
longer-lived positron-emitting radionuclides such as
64Cu,
86Y,
89Zr and
124I, and advances in chelation chemistry, have renewed
interest in the use of positron emission tomography with
radioimmunoconjugates (immunoPET) as a tool for providing
real-time, quantitative information on physiological response to
treatment.[2–5]
Proteins associated with the human epidermal growth-factor
receptor kinase (ERBB or HER) signaling network have proved to
be valuable targets for diagnostic imaging with radioimmunocon-
jugates due to their overexpression in various cancers phenotypes.
In particular, overexpression of HER2/neu (also known as ERBB2)
has been found to correlate with increased tumor aggression,
metastatic potential, and poor prognosis for disease-free survival in
patients with breast, colorectal, ovarian, lung, prostate and salivary
gland tumors.[6,7] The ERBB signaling network and the role of
PLoS ONE | www.plosone.org 1 January 2010 | Volume 5 | Issue 1 | e8859HER2/neu in cancer biology has been the subject of several
excellent reviews.[7–11]
HER2/neu has emerged as a key target for anticancer drugs due
to its intrinsic involvement in the phosphatidylinositol-3-kinase-
Akt/protein kinase B (PI3K-Akt) and the mitogen-activated
protein kinase (MAPK) pathways, both of which suppress
apoptosis and promote tumor cell survival, gene transcription,
angiogenesis, cellular proliferation, migration, mitosis, and differ-
entiation.[7] Three important classes of anti-HER2/neu therapeu-
tics include: mAbs directed against extracellular ligand-binding
and dimerization epitopes, tyrosine-kinase (TK) inhibitors and
Hsp90 inhibitors. Examples of each class include pertuzumab and
trastuzumab (which block dimerization and suppress signaling by
binding to extracellular domains II and IV, respectively); the
HER2/neu TK-inhibitor lapatinib; and Hsp90 inhibitors including
geldanamycin derivatives, SNX-5422, NVP-AUY922, BIIB021
and PU-H71.[7,11–18]
Trastuzumab (Herceptin
TM, Genentech) has been exploited as
both a therapeutic agent and radiotracer. Trastuzumab and
related mAb-fragments have been radiolabeled with a wide range
of radionuclides and quantitative immunoPET imaging has been
used to monitor the effect of administering Hsp90 inhibitors on
HER2/neu expression levels.[19–30] Quantification of changes in
HER2/neu expression in response to Hsp90 treatment has the
potential to facilitate patient-specific dose regimes. For example,
studies using
64Cu-labeled trastuzumab and
68Ga-labeled F(ab’)2-
trastuzumab have been reported.[19–21] However, both the
64Cu- and
68Ga-labeled agents are sub-optimal radiotracers. The
comparatively short half-life of
64Cu (t1/2=12.7 h) means that the
radionuclide has decayed before the intact antibody achieves
optimal biodistribution (ca. 4–5 days), and the small size the
F(ab’)2 fragments gives poor tumor-to-background tissue contrast
ratios.[1,2] In efforts to overcome these limitations in radiotracer
design, Orlova et al.[28] and Kramer-Marek et al.[29] explored the
potential of
124I- and
18F-labeled trastuzumab affibodies for
measuring HER2/neu expression, respectively.
Over recent years,
89Zr has emerged as a promising
radionuclide for use in immunoPET. In particular, facile methods
for radiolabeling intact mAbs with
89Zr have been developed from
the pioneering work of researchers at the Vrije University Medical
Center (Amsterdam, The Netherlands).[30–46] Zirconium-89 has
a number of distinct advantages which make it ideal for
immunoPET: (i) the half-life of 78.41 h matches closely the
extend times required for optimum biodistribution of intact mAbs,
(ii) the positron yield of 22.7% is comparable to that of
64Cu,
86Y
and
124I which improves counting statistics in PET imaging, (iii)
zirconium and its ions are generally inert to biological systems and
have no known biological role or function, (iv) cyclotron
production of
89Zr via the (p,n) transmutation reaction using a
100% naturally abundant
89Y solid target is highly efficient and
cost effective,[47] and (v) high purity and high specific-activity
89Zr is now available in various chemical forms which are suitable
for radiolabeling mAbs. Despite initial concerns over the radiation
dosimetry with
89Zr which stem from the presence of higher
energy c-rays (Ec=909.2 keV, Ic=99.0%), several clinical studies
in Europe have shown that a variety of
89Zr-labeled mAbs
targeting different tumor types are safe for use in humans.[44–46]
Furthermore, these clinical studies demonstrate the benefits of
89Zr-labeled mAbs, which in comparison to equivalent mAbs and
antibody fragments labeled with other PET radionuclides
including
64Cu,
68Ga,
86Y and
124I, display higher tumor uptake,
lower background tissue accumulation, improved image contrast
and more facile delineation of tumors in vivo. The use of intact
antibodies as the basis for radiotracer development, such as
trastuzumab which is used routinely in the clinic worldwide, also
has the advantage of expediting preclinical and clinical translation.
The work presented here describes the production of
89Zr-
radiolabeled trastuzumab and its ability to identify HER2/neu
positive tumors in vivo. During the course of our investigations,
Dijkers et al. reported initial studies on
89Zr-labeled trastuzumab in
the SKOV-3 xenograft model.[30] Our studies further investigate
the efficacy of
89Zr-DFO-trastuzumab as a radiotracer for
immunoPET and include detailed studies using the BT-474
(HER2/neu positive) and MDA-MB-468 (HER2/neu negative)
xenograft models. Our work also complements and extends the
methods of Smith-Jones et al.[20] which used
68Ga-labeled
trastuzumab fragments and 17-AAG for measuring pharmacody-
namic changes in HER2/neu expression in vivo to the full antibody
with the novel and more potent purine-based Hsp90 inhibitor,
PU-H71.[48] Studies include in vitro and in vivo by Western blot
analysis, acute biodistribution studies and immunoPET. The
results demonstrate
89Zr-radiolabeled trastuzumab has the poten-
tial to be used in the clinic as a radiotracer for both localizing and
staging of HER2/neu positive tumors, and in the long-term
measurements of the efficacy of treatment with Hsp90 inhibitors
such as PU-H71 and other drugs with extended pharmacody-
namic profiles.
Materials and Methods
All chemicals, unless otherwise stated, were purchased from
SigmaAldrich (St. Louis, MO) and were used as received. Water
(.18.2 MV.cm at 25uC, Milli-Q, Millipore, Billerica, MA) was
purified by passing through a 10 cm column of chelex resin (Bio-
Rad Laboratories, Hercules, CA) at a flow rate ,1.0 mL/min. All
instruments were calibrated and maintained in accordance with
previously reported routine quality-control procedures.[49] Activ-
ity measurements were made by using a Capintec CRC-15R Dose
Calibrator (Capintec, Ramsey, NJ) with a calibration factor of 465
for
89Zr. For accurate quantification of activities, experimental
samples were counted for 1 min. on a calibrated Perkin Elmer
(Waltham, MA) Automatic Wizard
2 Gamma Counter by using an
energy window of 800–1000 keV for
89Zr (909 keV emission).
89Zr-radiolabeling reactions were monitored by using silica-gel
impregnated glass-fibre instant thin-layer chromatography (ITLC-
SG) paper (Pall Corp., East Hills, NY) and analyzed on a radio-
TLC plate reader (Bioscan System 200 Imaging Scanner coupled
to a Bioscan Autochanger 1000 (Bioscan Inc., Washington, DC,
using Win-Scan Radio-TLC software version 2.2). Solvent systems
included diethylene triamine pentaacetic acid in water (DTPA,
50 mM, pH 7) and phosphate buffered saline (PBS). Human
breast cancer cell lines BT-474 and MDA-MB-468 were obtained
from the American Type Culture Collection (ATCC, Manassas,
VA) and were grown by serial passage. Full details for all methods
are provided in the supporting information (Text S1).
Trastuzumab Conjugation and Radiolabeling
Trastuzumab (Herceptin
TM, Genentech, South San Francisco,
CA) was conjugated to desferrioxamine B (DFO, Calbiochem,
Spring Valley, CA) by using procedures modified from those
described by Verel et al.[36] Full details are provided in the
supporting information (Text S1). Briefly, DFO-conjugated
trastuzumab (DFO-trastuzumab) was prepared via a 6-step
procedure involving: the reaction of DFO mesylate with succinic
anhydride to give N-succinyldesferrioxamine B; protection of the
tris-hydroxamate functional groups via Fe
3+ complexation; forma-
tion of the tetrafluorophenol (TFP) activated ester; mAb
conjugation; removal of the Fe
3+ via transchelation to EDTA;
89Zr-DFO-Trastuzumab ImmunoPET
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chromatography and/or spin-column centrifugal separation.
Zirconium-89 was produced via the
89Y(p,n)
89Zr transmutation
reaction on an EBCO TR19/9 variable-beam energy cyclotron
(Ebco Industries Inc., Richmond, British Columbia, Canada) in
accordance with previously reported methods.[36,47,50] The
[
89Zr]Zr-oxalate was isolated in high radionuclidic and radio-
chemical purity (RCP) .99.99%, with a specific-activity of 195–
497 MBq/mg, (5.28–13.43 mCi/mg).[47]
89Zr-DFO-trastuzumab was prepared by the complexation of
[
89Zr]Zr-oxalate with DFO-trastuzumab. Typical radiolabeling
reactions were conducted in accordance with the following
procedure. Briefly, [
89Zr]Zr-oxalate (29.7 MBq, [805 mCi]) in
1.0 M oxalic acid (40 mL) was adjusted to pH 7.7–8.5 with 1.0 M
Na2CO3(aq.). CAUTION: Acid neutralization releases CO2(g)
and care should be taken to ensure that no radioactivity escapes
the microcentrifuge vial. After CO2(g) evolution ceased, DFO-
trastuzumab (50 mL, 5.0 mg/mL [0.25 mg of mAb], in 0.9%
sterile saline) was added and the reaction was mixed gently. The
reaction was incubated at room temperature for 1–2 h and
complexation progress was monitored by ITLC (DTPA, 50 mM,
pH 7). After 1 h, high radiolabeling yields were obtained with
RCP .78(64)%.
89Zr-DFO-trastuzumab was purified by using
either size-exclusion chromatography (Sephadex G-25 M, PD-10
column, .30 kDa, GE Healthcare; dead-volume=2.5 mL, eluted
with 200 mL fractions of 0.9% sterile saline, Figure S1) or spin-
column centrifugation (4 mL volume, .30 kDa, Amicon Ultra-4,
Millipore, Billerica, MA; washed with 463 mL, 0.9% sterile
saline). The RCP of the final
89Zr-DFO-trastuzumab (.70%
radiochemical yield; formulation: pH 5.5–6.0; ,500 mL; 0.9%
sterile saline) was measured by both radio-ITLC and analytical
size-exclusion chromatography (,0.74 MBq [20 mCi], ca. 5–
10 mL aliquots) and was found to be .99% in all preparations.
In the ITLC experiment
89Zr-DFO-trastuzumab and [
89Zr]Zr-
DFO remain at the baseline (Rf=0.0), whereas
89Zr
4+(aq.) ions
and [
89Zr]Zr-DTPA elute with the solvent front (Rf=1.0).
Chelate Number
The number of accessible DFO chelates conjugated to
trastuzumab was measured by radiometric isotopic dilution assays
following a method similar to that described by Anderson et al (see
supporting information).[51,52] Full details are provided in the
supporting information (Text S1).
Immunoreactivity
The immunoreactive fraction of
89Zr-DFO-trastuzumab samples
was determined by using specific radioactive cellular-binding assays
following modified procedures derived from Lindmo et al.[53]
Briefly, BT-474 or MDA-MB-468 cells were suspended in micro-
centrifuge tubes at concentrations of 5.0, 4.0, 3.0, 2.5, 2.0, 1.5, and
0.5610
6 cells/mL in 500 mL PBS (pH 7.4). Aliquots of
89Zr-DFO-
trastuzumab (50 mL of a stock solution of ,0.37 kBq, [,0.01 mCi]
in 10 mL of 1% bovine serum albumin [BSA]; 2 kBq [0.05 mCi],
0.02 mg of mAb) were added to each tube (n=3; final volume:
550 mL) and the samples incubated on an orbital mixer for 60 min.
at room temperature. Cells were then pelleted by centrifugation
(600G for 2 min.), resuspended and washed twice with ice-cold PBS
before removing the supernatant and counting the
89Zr-activity
associated with the cell pellet. The count data were background
corrected and compared with the total number of counts in control
samples. Competitive inhibition (blocking) studies were conducted
by using the same procedure but with the addition of non-
radiolabeled trastuzumab (50 mL, 2 mg/mL in 1% BSA, [.5000-
fold excess mAb; 100 mg]) to the
89Zr-DFO-trastuzumab solutions.
Immunoreactive fractions were determined by linear regression
analysis of a plot of (total/bound) activity versus (1/[normalized cell
concentration]), and calculated as 1/y-intercept. Full details are
provided in the supporting information (Text S1).
Stability Studies
The stability of
89Zr-DFO-trastuzumab with respect to
radiochemical purity, loss of radioactivity from the mAb and
change in immunoreactivity was investigated in vitro by incubation
in solutions of 0.9% saline, DTPA (50 mM, pH 7) and human
serum for 7 days at 37uC. The radiochemical purity and degree of
transchelation to DTPA was determined by radio-ITLC and c-
counting, and the immunoreactive fraction was measured by the
cellular-binding assay (vide supra).
Xenograft Models
All animal experiments were conducted in compliance with the
guidelines of the Institutional Animal Care and Use Committee
(IACUC) of MSKCC. Female athymic nu/nu mice (NCRNU-M,
20–22 g, 6–8 weeks old) were obtained from Taconic Farms Inc.
(Hudson, NY), and were acclimated to the MSKCC vivarium for 1
week prior to implanting tumors. Mice were provided with food
and water ad libitum. Tumors were induced on a shoulder by sub-
cutaneous (s.c.) injection of 5.0–10.0 (610
6) cells in a 200 mL cell
suspension of a 1:1v/v mixture of media with reconstituted
basement membrane (BD Matrigel
TM, Collaborative Biomedical
Products Inc., Bedford, MA).[54] For animals bearing two tumors
used in the immunoPET studies, BT-474 and MDA-MB-468 cells
were implanted s.c. on the left and right shoulder/flank,
respectively. Palpable tumors developed after a period of 14–18
days and the tumor volume (V/mm
3) was estimated by external
vernier caliper measurements (Full details are provided in the
supporting information (Text S1)).[55]
Acute Biodistribution Studies
Acute in vivo biodistribution studies were conducted to evaluate
the uptake of
89Zr-DFO-trastuzumab in mice bearing s.c. BT-474
tumors (90–170 mm
3). Mice were randomized before the study and
were warmed gently with a heat lamp 5 min. before administering
89Zr-DFO-trastuzumab (0.55–0.74 MBq, [15–20 mCi], 5–7 mgo f
mAb, in 200 mL 0.9% sterile saline) via intravenous (i.v.) tail-vein
injection (t=0 h). Animals (n=3–8, per group) were euthanized by
CO2(g) asphyxiation at 1, 12, 24, 48, 72 and 120 h post-injection
and 12 organs (including the tumor) were removed, rinsed in water,
dried in air for 5 min., weighed and counted in a gamma-counter
for
89Zr-activity. The mass of
89Zr-DFO-trastuzumab formulation
injected into each animal was measured and used to determine the
total number of counts (counts per minute, [c.p.m.]) by comparison
to a standard syringe containing and independently measured
activity and mass. Count data were background and decay-
corrected to the time of injection and the percent injected dose
per gram (%ID/g) for each tissue sample calculated by normaliza-
tion to the total activity injected.
The effects of pre-administering PU-H71 (intraperitoneal (i.p.),
75 mg/kg, 200 mL of PU-H71-hydrochloride dissolved in 10 mM
phosphate buffer [PB]) 4 h prior to i.v. injection of
89Zr-DFO-
trastuzumab, were also investigated by acute biodistribution
studies at 12, 24, 48 and 72 h.
Competitive inhibition studies were also performed to investi-
gate the specificity of
89Zr-DFO-trastuzumab for HER2/neu. Non-
radiolabeled trastuzumab (10 mg/kg solution in 0.9% sterile
saline, 0.2 mg/mouse) was added to the
89Zr-DFO-trastuzumab
formulation to reduce the specific-activity (30–40-fold decrease:
89Zr-DFO-Trastuzumab ImmunoPET
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studies were performed at 24 h post-i.v. administration.
Pharmacodynamic Studies
Changes in the expression levels of HER2/neu in response to
Hsp90 inhibition were investigated by in vivo pharmacodynamic
(PD) studies. Prior to BT-474 cell inoculation, mice were
implanted s.c. with 0.72 mg sustained release 17b-estradiol pellets
by using a 10 g trocar. Tumors were established as described
above and were allowed to grow to 6–8 mm in diameter (120–
270 mm
3) before commencing treatment. Mice (n=2, per group)
bearing s.c. BT-474 tumors were administered PU-H71 (as the
hydrochloride salt, i.p., 75 mg/kg, 200 mL, 10 mM PB). Animals
were euthanized by CO2(g) asphyxiation at 12, 24, 48, 72 and
96 h post-i.p. administration of PU-H71 and tumors were
collected. For protein analysis, tumors were homogenized in
SDS lysis buffer (50 mM Tris, pH 7.4, 150 mM NaCl, and 1%
Nonidet P-40) and subjected to Western blot analysis (vide infra).
Western Blots
BT-474 cells were grown to 60–70% confluence and treated
with either PU-H71 (in 10 mM PB) at various concentrations or
DMSO for the specified time. Lysates were prepared by using
50 mM Tris, pH 7.4, 150 mM NaCl, and 1% Nonidet P-40 lysis
buffer. Protein concentrations were determined by using the
bicinchoninic acid (BCA) Protein Assay kit (Pierce, Rockford, IL)
in accordance with the manufacturer’s protocol. Protein lysates
(20–100 mg) were resolved electrophoretically by SDS-PAGE,
transferred to nitrocellulose membrane, and then probed with the
specified primary antibodies: anti-HER2 from rabbit (1:250,
280004; Zymed Laboratories Inc., South San Francisco, CA);
anti-PARP (p85 fragment) from rabbit (1:250, G7341; Promega,
Madison, WI); anti-phospho-Akt (Ser 473) from rabbit (1:500,
9271S; Cell Signaling); anti-Akt from rabbit (1:500, 9272; Cell
Signaling Technology Inc., Danvers, MA); anti-Hsp70 from
mouse (1:500, SPA-810; Stressgen, Ann Arbor, MI); anti-Hsp90
from mouse (1:500, SPA-830; Stressgen); and anti-Raf-1 from
rabbit (1:300, sc-133; Santa Cruz Biotechnology Inc., Santa Cruz,
CA). Membranes were then incubated with a 1:5,000 dilution of a
corresponding peroxidase-conjugated secondary antibody. Equal
loading of the protein samples was confirmed by parallel Western
blots for b-actin (1:5,000, ab8227–50; Abcam Inc., Cambridge,
MA). Detection was performed by using the ECL-Enhanced
Chemiluminescence Detection System (Amersham Biosciences,
Fairfield, CT) according to the manufacturer’s instructions. Blots
were visualized by autoradiography.[48] Gels were scanned using
Adobe Photoshop 7.0.1 and semi-quantitative densitometric
analysis was performed by using Un-Scan-It software.
Small-Animal ImmunoPET Imaging
PET imaging experiments were conducted on a microPET
Focus 120 rodent scanner (Concorde Microsystems).[56] Mice
were administered
89Zr-DFO-trastumab formulations (8.50–
9.25 MBq, [230–250 mCi], 80–90 mg of mAb, in 200 mL 0.9%
sterile saline for injection) via tail-vein injection. The effects of pre-
administering PU-H71 (i.p., 75 mg/kg, 200 mL of PU-H71-
hydrochloride dissolved in 10 mM phosphate buffer [PB]) or
vehicle-control, 4 h prior to i.v. injection of
89Zr-DFO-trastuzu-
mab, were also investigated by immunoPET. Approximately 5
minutes prior to recording PET images, mice were anesthetized by
inhalation of 2% isoflurane (Baxter Healthcare, Deerfield, IL)/
oxygen gas mixture and placed on the scanner bed; anesthesia was
maintained using 1% isoflurane/oxygen gas mixture. PET data
were recorded at various time-points between 1–120 h. List-mode
data were acquired for 10–30 min. using a c-ray energy window of
350–750 keV, and a coincidence timing window of 6 ns. Images
were analyzed by using ASIPro VM
TM software (Concorde
Microsystems). Full experimental details are presented in the
supporting information. Full details are provided in the supporting
information (Text S1).
Statistical Analysis
Data were analyzed by the unpaired, two-tailed Student’s t-test.
Differences at the 95% confidence level (P,0.05) were considered
to be statistically significant.
Results and Discussion
During the course of our investigations, Dijkers et al. reported
initial studies using
89Zr-labeled trastuzumab in SKOV-3 (HER2/
neu positive) xenograft models.[30] In these studies we have
extended the use
89Zr-DFO-trastuzumab to investigate uptake in
the BT-474 (HER2/neu positive) and MDA-MB-468 (HER2/neu
negative) xenograft models. We have also explored the potential of
89Zr-DFO-trastuzumab to be used as a non-invasive radiotracer
for qualitative and quantitative delineation of the efficacy of Hsp90
inhibitor treatment (namely PU-H71) on HER2/neu expression
levels in vivo.
89Zr-DFO-Trastuzumab Was Produced in High Yield and
Specific-Activity
Trastuzumab was functionalized with the hexadentate, trihy-
droxamate chelate, desferrioxamine B (DFO) by using bioconju-
gation methods modified from the pioneering work of Verel
et al.[36] Previous studies have shown that although DTPA can be
used for chelation and radiolabeling of mAbs with
89Zr
4+ ions,
demetalation occurs in vivo and at present DFO remains the
chelate of choice.[31,33,47] Despite the multi-step functionaliza-
tion methods involving protection/deprotection using Fe
3+ ions
the conjugation and purification chemistry was found to proceed
in moderate-to-high yield (60–78%) with high purity. Radiolabel-
ing of sterile DFO-trastuzumab with either [
89Zr]Zr-oxalate or
[
89Zr]Zr-chloride was achieved at room temperature in alkaline
solutions (pH 7.7–8.5) with crude radiochemical yields (.95%,
n=15). Facile purification of
89Zr-DFO-trastuzumab from small-
molecule radiolabeled impurities can be achieved by using either
size-exclusion chromatography or spin-column centrifugation.
The final radiochemical yield of purified
89Zr-DFO-trastuzumab
was .70% and the product was formulated in either PBS or 0.9%
sterile saline with RCP .99% (n=12) and a specific-activity of
104.362.1 MBq/mg (2.8260.05 mCi/mg) of mAb. The specific-
activity obtained in our studies compares favorably with the
previously reported specific-activity of 67.262.4 MBq/mg
(1.8260.07 mCi/mg).[30] Isotopic dilution assays revealed an
average of 6.860.8 accessible chelates per mAb.
89Zr-DFO-Trastuzumab Is Stable and Immunoreactive In
Vitro
Incubation of
89Zr-DFO-trastuzumab in either 0.9% sterile
saline or human serum for 7 days at 37uC revealed ,2% decrease
in RCP (via demetalation) with a ,27% decrease in immunore-
active fraction (0.6060.02). In contrast, experiments conducted in
DTPA (50 mM, pH 7) showed a 5562% decrease in RCP after 7
days. DTPA represents a particularly strong ligand challenge and
overall these results are consistent with other reports which
indicate that
89Zr-DFO-mAbs display high kinetic stability and are
suitable for further in vivo studies.[30,35,40,43–45]
89Zr-DFO-Trastuzumab ImmunoPET
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89Zr-DFO-trastuzumab
formulations was measured by specific in vitro cellular association
assays using BT-474, HER2/neu positive cells prior to each in vivo
experiment (Figure 1).[53] The average immunoreactive fraction
of
89Zr-DFO-trastuzumab was found to be 0.8760.07 (n=18).
Control experiments (n=3) using the HER2/neu negative MDA-
MB-468 cell line or BT-474 cells with low specific-activity
formulations (0.3760.1 MBq/mg [10.260.2 mCi/mg]) in which
a .5000-fold excess of non-radiolabeled trastuzumab was added
to the reactions showed no binding and demonstrated the
specificity of
89Zr-DFO-trastuzumab for HER2/neu expressing
cells (Figures S2A and S2B).
In Vitro Pharmacodynamic Studies Demonstrate the
Effects of PU-H71 on HER2/neu Expression
In HER2/neu positive tumors, Hsp90 has been shown to
regulate the expression levels of a variety of onco-proteins
including HER2/neu.[18,57] In vitro Western blot studies
showed that treatment of BT-474 cells with varying concen-
trations of PU-H71 (1–0.01 mM, Figure S3) for 24 h led to
changes in expression levels of proteins associated with the
ERBB signaling cascade (Figure 2). In each case, expression
levels of the Hsp90-independent protein b-actin, was used as a
protein loading control. Consistent with the Hsp90-mediated
mechanism of action, PU-H71 treatment at concentrations
$0.25 mM, decreased expression levels of Hsp90 client onco-
proteins including HER2/neu, Akt and RAF1, compared to
DMSO-treated controls. Degradation of Akt and phosphory-
lated Akt (P-Akt) leads to inactivation of cell survival pathways
and the observed concomitant increase in levels of cleaved
poly-(ADP-ribose) polymerase (cPARP) is indicative of apopto-
sis. Decreased expression levels of RAF1 demonstrate that PU-
H71 inhibition of Hsp90 also inhibits the MAPK signaling
pathway, consequently suppressing the transcription of genes
associated with cell survival, angiogenesis, proliferation, migra-
tion, mitosis, and differentiation. Experiments also revealed
that expression levels of Hsp90 remained constant with varying
PU-H71 concentrations but Hsp70 levels increased in response
to Hsp90 inhibition at concentrations of approximately 0.1–
0.25 mM.
Biodistribution Studies Show Specific Uptake of
89Zr-DFO-Trastuzumab in BT-474 Tumors
The ability of
89Zr-DFO-trastuzumab to target HER2/neu
receptors in vivo was initially assessed by conducting acute
biodistribution studies in BT-474 tumor-bearing mice at 1, 12,
24, 48, 72 and 120 h post-i.v. administration (Tables 1 and S1,
and Figure 3). The data reveal that high tumor uptake is observed
24 h post-injection (64.68613.06%ID/g) with
89Zr accumulation
in the tumors reaching a peak between 48 and 72 h. Retention of
89Zr was observed for over 120 h (75.54613.47%ID/g) with only
a small decrease (9.64%ID/g, [P=0.28]) in the mean uptake
compared to that at 72 h.
Competitive inhibition studies using low specific-activity formu-
lations (30–40-fold decrease: 2.60–3.65 MBq/mg [0.07–0.1 mCi/
mg]) revealed only 13.5064.84%ID/g tumor uptake at 24 h post-
injection; an approximate 5-fold decrease (P,0.00001) versus high
specific-activity formulations (Figure 3A). These experiments
concur with the in vitro data and demonstrate the specificity of
89Zr-DFO-trastuzumab for the HER2/neu antigen in vivo.
The pharmacodynamic effects of administering PU-H71 on
89Zr-DFO-trastuzumab uptake in BT-474 tumor-bearing mice
were also investigated by using acute biodistribution studies
(Table 1 and S1, and Figure 3B) and Western blot analysis of tissue
samples (Figure 4). Animals were treated with a single dose of PU-
H71 4 h prior to i.v. injection of
89Zr-DFO-trastuzumab (t=0h)
and biodistribution studies were conducted at 12, 24, 48 and 72 h.
The biodistribution data show that at 24 and 48 h post-injection,
Figure 1. Plot of the (total/bound) activity versus (1/[normal-
ized cell concentration]), used to calculate the immunoreac-
tivity fraction of
89Zr-DFO-trastuzumab in BT-474 (HER2/neu
positive) cells by extrapolation to infinite antigen excess (1/y-
intercept).
doi:10.1371/journal.pone.0008859.g001
Figure 2. In vitro Western blots showing the change in protein
expression levels in response to treatment with PU-H71 at
0.01–1 mM concentrations. DMSO vehicle treated experiments and
b-actin are include as controls. Proteins investigated include: HER2/neu;
Akt; phosphorylated Akt (P-Akt); the apoptosis marker, cleaved poly
(ADP-ribose) polymerase (cPARP); RAF1; Hsp90; Hsp70; and b-actin as a
protein loading control.
doi:10.1371/journal.pone.0008859.g002
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g and 41.4263.64%ID/g, respectively. Thus, in comparison with
control experiments, PU-H71 inhibition of Hsp90 and degrada-
tion of HER2/neu results in approximately 50% decrease in
89Zr-
DFO-trastuzumab tumor uptake at 24 and 72 h (Table S2;
Control-to-PU-H71-treated %ID/g ratios of 2.17 [P=0.0001]
and 1.73 [P=0.026], respectively). By 72 h post-administration,
89Zr-DFO-trastuzumab tumor uptake in PU-H71-treated mice
(73.64612.17%ID/g) returned to the same levels as observed in
the control experiments (85.18611.10%ID/g, [P=0.244]). Im-
portantly,
89Zr-DFO-trastuzumab uptake in all background tissues
remained the same in control and PU-H71 treated animals. This
observation demonstrates the specificity of PU-H71 for HER2/neu
over-expressing BT-474 tumors.
The
89Zr-DFO-trastuzumab biodistribution data suggest that a
single-dose of PU-H71 induces a sustained effect in terms of
HER2/neu and other client oncoprotein degradation for at least
48 h post-administration. This observation was confirmed by
Table 1. Biodistribution data of
89Zr-DFO-trastuzumab versus time/h, administered by i.v. tail-vein injection to female, athymic nu/
nu mice bearing s.c. BT-474 tumors (90–150 mm
3).
a,b
89Zr-DFO-trastuzumab (5–7 mg mAb)
Organ 1 h (n=5) 12h(n=4) 24h(n=8) 48h(n=3) 72h(n=8) 120 h (n=4)
Blood 45.2969.33 23.7063.28 18.6863.12 18.8363.35 17.2365.06 11.0566.98
Tumor 7.3563.22 23.8063.37 64.68613.06 71.71610.35 85.18611.10 75.54613.47
Heart 12.6163.38 8.2263.46 5.0560.90 6.5861.98 4.7561.62 3.2561.35
Lung 18.0963.48 14.5062.79 12.3661.87 13.0262.72 12.7663.78 7.1164.07
Liver 21.1864.97 8.4460.98 10.1061.02 9.9661.99 9.4861.13 10.5562.78
Spleen 22.5068.89 7.8561.28 10.9262.29 6.3461.69 10.8263.80 10.8563.18
Kidney 12.0262.72 8.4360.63 7.2860.66 7.5961.21 7.7561.23 6.4861.67
Muscle 0.6860.08 1.3660.38 1.2260.18 1.1260.26 1.2560.40 1.0360.42
Bone 5.6460.90 1.9360.71 3.6761.71 1.6860.47 4.7960.65 6.8663.02
Tumor/Blood 0.1760.09 1.0660.23 3.5060.78 3.9161.04 5.1861.90 5.6862.13
Tumor/Heart 0.6460.32 3.5262.03 12.9462.75 11.7164.44 19.5966.30 20.2665.81
Tumor/Lung 0.4460.27 1.8060.72 5.2560.90 5.7561.90 7.0962.47 9.2763.62
Tumor/Liver 0.3660.14 2.8660.74 6.3961.11 7.3761.54 9.4461.98 8.2061.54
Tumor/Spleen 0.3360.09 2.9360.88 5.9961.04 11.8463.25 9.2162.59 8.0661.48
Tumor/Kidney 0.6660.36 2.9560.62 8.8361.36 9.6562.33 10.9861.59 10.5462.40
Tumor/Muscle 11.3065.80 18.3469.95 54.2765.07 67.8064.51 75.8166.63 67.6765.94
Tumor/Bone 1.3260.55 10.0161.50 9.6366.73 45.55616.54 18.4164.90 14.2162.79
Block (200 mg mAb) PU-H71 treated (5–7 mg mAb)
Organ 24 h (n=4) 12h(n=5) 24h(n=5) 48h(n=4) 72h(n=5)
Blood 47.02612.72 24.8961.54 20.7967.20 21.5963.67 22.6366.88
Tumor 13.5064.84 14.5562.75 29.7564.43 41.4263.64 73.64612.17
Heart 12.5863.95 8.3661.67 5.0160.63 4.4861.51 5.6960.45
Lung 25.2867.34 15.6461.85 12.8465.39 13.5563.82 13.1663.45
Liver 28.3765.49 9.7461.20 10.0261.80 11.4661.52 12.8961.04
Spleen 33.2268.01 9.9462.01 11.2062.52 10.1562.44 12.6664.92
Kidney 12.3362.39 8.8961.00 8.4661.81 7.6461.07 9.5561.59
Muscle 0.8760.17 1.1860.15 1.2760.23 0.9760.28 1.5560.40
Bone 7.7962.39 2.6660.99 5.0962.32 2.2360.47 5.2761.48
Tumor/Blood 0.3360.20 0.5560.09 1.5360.51 1.9660.23 3.3660.52
Tumor/Heart 1.2860.89 1.7660.82 6.2261.56 8.1661.09 12.8961.16
Tumor/Lung 0.6760.23 0.8960.06 2.7461.28 3.5560.64 5.7060.61
Tumor/Liver 0.4860.30 1.4360.05 3.2760.77 3.7960.39 5.7861.36
Tumor/Spleen 0.5060.20 1.3660.02 2.8260.85 4.6860.18 6.5462.81
Tumor/Kidney 1.1760.56 1.4960.30 3.5460.44 5.1660.13 7.7160.28
Tumor/Muscle 16.6167.61 12.5461.35 24.9062.74 36.9361.47 48.4765.39
Tumor/Bone 1.9061.03 4.6460.92 7.8663.86 21.1765.14 14.9865.44
aComplete biodistribution data are presented in the supporting information (Table S1).
bThe data are expressed as the mean %ID/g 6 one standard deviation (S.D.).
doi:10.1371/journal.pone.0008859.t001
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homogenized tumor tissue samples obtained at 0, 12, 24, 48, 72
and 96 h post-i.p. administration of PU-H71 in BT-474 tumor-
bearing mice (Figures 4A and B). As with the in vitro experiments,
PU-H71 was found to inhibit Hsp90 as indicated by the specific
tumor fingerprints which showed increased Hsp70 expression,
degradation of P-Akt and high levels of cPARP between 24 and
72 h. The data confirm that PU-H71 degrades HER2/neu levels to
,20% of initial levels for up to 48 h. HER2/neu expression was
found to return to baseline levels by 72 h. The recovery of HER2/
neu expression between 48 and 72 h is consistent with the increase
in
89Zr-DFO-trastuzumab uptake observed in the biodistribution
studies.
ImmunoPET Studies Demonstrate the Use of
89Zr-DFO-Trastuzumab as a Radiotracer
ImmunoPET images of
89Zr-DFO-trastuzumab recorded in
BT-474 and MDA-MB-468 tumor-bearing mice between 1 to
120 h are presented in Figures 5A and B, respectively. Radiotracer
uptake in BT-474 tumors was observed in ,5 h post-injection of
89Zr-DFO-trastuzumab and high tumor-to-muscle (T/M) ratios
(calculated by using both region-of-interest mean and maximum
%ID/g values from the PET images; Figure 6 and Table S3) were
observed. At 5 h post-injection mean and maximum T/M ratios
for radiotracer uptake in BT-474 tumor-bearing mice were found
to be 7.87 and 11.90, respectively. In contrast, low
89Zr-DFO-
trastuzumab accumulation in HER2/neu negative MDA-MB-468
tumors (mean and maximum T/M ratios of 2.26 and 4.15,
respectively) was found to occur in accordance with the ‘‘enhanced
permeation and retention’’ (EPR) mechanism.[58]
Quantification of the immunoPET images showed that at 48
and 72 h time points, the absolute uptake of
89Zr-DFO-
trastuzumab was around 16.0%ID/g in BT-474 tumors and
4.5%ID/g in MDA-MB-468 tumors (Figure 6). These data show
that
89Zr-DFO-trastuzumab immunoPET imaging provides very
high tumor-to-background tissue (T/B) ratios. Although the
models are not identical which prevents direct comparison, the
high contrast observed in the immunoPET images with
89Zr-
DFO-trastuzumab compare favorably with those obtained using
other mAb and mAb-fragments labeled with
64Cu,
68Ga,
86Y,
99mTc,
111In or
124I. [19–30] Although the immunoPET images
demonstrated very high contrast for radiotracer uptake in BT-474
tumors, quantitative analysis suggests that
89Zr-DFO-trastuzumab
is approximately 5-fold lower than was observed in the
biodistribution experiments. This discrepancy is explained by
Figure 3. Bar charts showing selected tissue biodistribution
data (%ID/g) for (A) uptake of high and low specific-activity
formulations of
89Zr-DFO-trastuzumab in BT-474 tumor-bear-
ing mice, and (B)
89Zr-DFO-trastuzumab uptake in control
(vehicle-treated) and PU-H71 treated animals at 12, 24, 48 and
72 h post-i.v. administration of
89Zr-DFO-trastuzumab (0.55–
0.74 MBq, 5–7 mg of mAb, in 200 mL 0.9% sterile saline).
doi:10.1371/journal.pone.0008859.g003
Figure 4. Pharmacodynamic studies on protein expression
levels in BT-474 tumor tissue samples obtained at 12, 24, 48,
72 and 96 h after PU-H71 treatment.
doi:10.1371/journal.pone.0008859.g004
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between the two experiments. For the immunoPET experiments a
total of 80–90 mg of trastuzumab was administered, whereas in the
biodistribution assays only 5–7 mg was used. The use of different
total doses of trastuzumab is unavoidable given the limitations in
sensitivity of small-animal PET detection which requires larger
amounts of administered activity than simple biodistribution
experiments. In humans undergoing trastuzumab therapy, the
mAb is administered at concentrations .5 mg/kg.[59] Based on
the human values, a therapeutic dose of trastuzumab in a typical
20–25 g mouse, corresponds to 100–125 mg of mAb. Consequent-
ly, the specific-activity of
89Zr-DFO-trastuzumab becomes a factor
in determining the precise correlation between the uptake values
obtained from the biodistribution and quantitative immunoPET
images. In other words, at the specific-activity obtained, the
amount of mAb administered in the immunoPET experiments
causes approximately 80% competitive binding (blocking) of
available HER2/neu antigens with non-radiolabeled trastuzumab.
Importantly, previous studies in our laboratory using the Focus
120 microPET and ‘‘non-saturating’’ PET radiotracers have
demonstrated close agreement between imaging and biodistribu-
tion-derived activity concentrations.
ImmunoPET studies were also used to visualize and quantify
the pharmacodynamic effects of PU-H71 treatment in dual tumor-
bearing mice. The immunoPET images (Figure 7) and time-
activity curves (TACs; Figure 6) show that in PU-H71 treated
mice, no difference was observed in either the mean or maximum
T/M ratios between BT-474 and MDA-MB-468 tumors. For
example, 24 h after administering
89Zr-DFO-trastuzumab mean
T/M ratios in PU-H71-treated mice were measured as 2.57 and
3.00 in BT-474 and MDA-MB-468 tumors, respectively (Figure 7
and Table S3).
In contrast, large differences were observed in the measured T/
M ratios between BT-474 (T/M=7.63) and MDA-MB-468 (T/
M=2.82) tumors in vehicle-treated mice. At longer time points,
mean T/M ratios for BT-474 tumors in vehicle-treated mice
remained constant at 48 h (7.85) but decreased slightly by 72 h
(6.71) and 120 h (6.77).
The approximate 3-fold decrease in BT-474 T/M ratios
between the vehicle-treated and PU-H71 treated mice is consistent
with the decrease in HER2/neu expression levels observed by in
vivo Western blots (Figure 4). Furthermore, the slight decrease in
tumor uptake between 72 and 120 h is consistent with the
9.6%ID/g decrease in BT-474 tumor uptake observed from the
Figure 5. ImmunoPET images of
89Zr-DFO-trastuzumab (8.50–9.25 MBq, 80–90 mg of mAb, in 200 mL 0.9% sterile saline) recorded in
(A) BT-474 (left shoulder) and (B) MDA-MB-468 (right flank) tumor-bearing mice between 1–120 h post-injection. The transverse (top)
and coronal (bottom) planar images intersect the center of the tumors.
doi:10.1371/journal.pone.0008859.g005
Figure 6. Time-activity curves derived by region-of-interest
analysis of the immunoPET images showing the mean %ID/g
tissue uptake versus time/h, for control and PU-H71-treated
mice bearing both BT-474 and MDA-MB-468 tumors.
doi:10.1371/journal.pone.0008859.g006
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time points is potentially indicative of a slow rate of metabolism
and excretion of
89Zr
4+ after internalization of HER2/neu-bound
89Zr-DFO-trastuzumab (Figures S4 and S5, and Table S4).
At late time points, the biodistribution data for
89Zr-DFO-
trastuzumab show residual uptake in the bone (4.7960.65%ID/g
and 6.8663.02%ID/g at 72 and 120 h, respectively). This bone
uptake was confirmed by immunoPET, and images of
89Zr-DFO-
trastuzumab at 120 h displayed low liver uptake but slightly higher
activity in the joints of the hind legs. It is plausible that a slow rate
of intratumoral metabolism of
89Zr-DFO-trastuzumab leads to the
transmetalation of
89Zr
4+ ions to a species which is either excreted
or sequestered in bone. However, our stability studies and
biodistribution data, along with previous reported investigations
on other
89Zr-DFO-labeled antibodies suggest that metabolism is
very limited.[44–46] Full metabolism studies are beyond the scope
of this work but further investigations on the fate of
89Zr-DFO-
trastuzumab in vivo are underway.
The studies reported here are consistent with previous
investigations and confirm that
89Zr is a suitable radionuclide
for labeling full, intact antibodies (,150 kDa).[30] The favorable
chemistry and image characteristics mean that
89Zr has the
potential to solve problems associated with, for example, non-
optimal half-life (
64Cu,
86Y), high uptake in background tissue
(
64Cu,
68Ga,
124I), low in vivo stability (
124I; particularly with
internalizing antibody-antigen constructs) and poor dosimetry
(
86Y). Furthermore, these studies demonstrate that immunoPET
with
89Zr-labeled mAbs can be used for both localizing tumors and
measuring the long-term effects (.5 days) of drug treatment from
a single radiotracer injection. Such measurements cannot be
achieved by using previous
64Cu-,
86Y-,
99mTc-, and
124I-
radiolabeled trastuzumab constructs. Along with
18F-labeled
trastuzumab affibodies[29],
89Zr-DFO-trastuzumab represents
one of the most promising radiotracers for non-invasive immuno-
PET measurements of HER2/neu expression in vivo. These studies
also showed that, unlike most tyrosine-kinase inhibitors, PU-H71
displays an extended pharmacodynamic profile for Hsp90
inhibition at time points .24 h, and this window of activity is
ideal for immunoPET imaging with radioimmunoconjugates such
as
89Zr-DFO-trastuzumab. As the pharmacodynamic change in
HER2/neu expression levels is indicative of the potential anti-
tumor effects of PU-H71,
89Zr-DFO-trastuzumab may also be
used to further the clinical development of this, and related Hsp90
inhibitors, by evaluating the dose delivered to the tumor and
quantifying the magnitude of the therapeutic response. These
immunoPET studies demonstrate that
89Zr-DFO-trastuzumab has
the potential to be used in the clinic as a specific radiotracer for
measuring the long-term effects of treatment with Hsp90
inhibitors.
In conclusion,
89Zr-DFO-trastuzumab has been prepared with
high radiochemical purity and specific-activity using methods
adapted from the literature. The immunoconjugate was found to
be stable with respect to loss of the radiolabel in vitro and
immunoreactivity assays demonstrated that conjugation, radiola-
beling and purification chemistries do not compromise the binding
affinity or specificity for the HER2/neu antigen. Biodistribution
and immunoPET experiments indicated that
89Zr-DFO-trastuzu-
mab shows excellent potential as a radiotracer for specific non-
invasive delineation of HER2/neu positive breast tumors in vivo.
Furthermore, unlike other trastuzumab constructs radiolabeled
with shorter-lived nuclides,
89Zr-DFO-trastuzumab may be used
to measure the long-term pharmacodynamic effects and poten-
tially patient response to treatment using Hsp90 inhibitors
including PU-H71. Work towards the clinical translation of
89Zr-DFO-trastuzumab and other
89Zr-labeled mAbs is underway.
Supporting Information
Text S1 Supplementary Materials and Methods.
Found at: doi:10.1371/journal.pone.0008859.s001 (0.07 MB
DOC)
Figure S1 Typical elution profiles observed by using PD-10 size-
exclusion chromatography for the purification of
89Zr-DFO-
trastuzumab from small molecule (,30 kDa)
89Zr-radiolabeled
impurities and unreacted [
89Zr]Zr-oxalate (complexed as
[
89Zr]Zr-DTPA). Species with molecular weights .30 kDa elute
in the first ,2.0 mL of solvent. The two peaks for crude and
purified
89Zr-DFO-trastuzumab have the same retention time
within the full-width half-maximum (FWHM).
Found at: doi:10.1371/journal.pone.0008859.s002 (0.14 MB TIF)
Figure S2 (A) Competitive inhibition (blocking) studies. (B)
Cellular association with MDA-MB-468 (HER2/neu -ve) cells.
Found at: doi:10.1371/journal.pone.0008859.s003 (0.25 MB TIF)
Figure S3 Chemical structure of PU-H71
Found at: doi:10.1371/journal.pone.0008859.s004 (0.05 MB TIF)
Figure 7. Coronal immunoPET images of control (left) and PU-H71 (right) treated mice bearing s.c. BT-474 and MDA-MB-468
tumors recorded at 24 h post-i.v. administration of
89Zr-DFO-trastuzumab. Mean and maximum T/M ratios obtained from VOI analysis are
presented (Table S3). For the control animal, the two coronal PET slices lie through the center of the HER2/neu positive and negative tumors.
doi:10.1371/journal.pone.0008859.g007
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coincident counts recorded via immunoPET imaging of BT-474
tumor-bearing mice (n=4) versus time/h. Exponential decay
regression analysis has been used to calculate the effective lifetime
(teff/h) and decay constant (leff/h
21) from which the estimated
observed and biological half-lives (t1/2.eff and t1/2.biol) have been
calculated.
Found at: doi:10.1371/journal.pone.0008859.s005 (0.13 MB TIF)
Figure S5 Plot of the total normalized, average number of
coincident counts recorded via immunoPET imaging of MDA-
MB-468 tumor-bearing mice (n=4) versus time/h. Exponential
decay regression analysis has been used to calculate the effective
lifetime (teff/h) and decay constant (leff/h
21) from which the
estimated observed and biological half-lives (t1/2.eff and t1/2.biol)
have be calculated.
Found at: doi:10.1371/journal.pone.0008859.s006 (0.13 MB TIF)
Table S1 Biodistribution data of
89Zr-DFO-trastuzumab versus
time/h, administered by i.v. tail-vein injection to female, athymic
nu/nu mice bearing s.c. BT-474 tumors (90–150 mm
3).
a
Found at: doi:10.1371/journal.pone.0008859.s007 (0.11 MB
DOC)
Table S2 A comparison of the difference between mean BT-474
tumor uptake values observed in the biodistribution studies in
control (vehicle-treated) and PU-H71 treated mice.
Found at: doi:10.1371/journal.pone.0008859.s008 (0.04 MB
DOC)
Table S3 Tumor-to-muscle (T/M) ratios have been calculated
from volume-of-interest (VOI) analysis of immunoPET images
recorded in dual tumor-bearing (BT-474 and MDA-MB-468)
female, athymic nu/nu mice between 1–120 h post-i.v. adminis-
tration of
89Zr-DFO-trastuzumab. The data presented are ratios
of mean and maximum (%ID/g) values. Errors associated with
VOI activity measurements are large and are strongly dependent
on the number and definition of each ROI used in the
determination of the VOI. As a consequence of the large errors
associated with VOI analysis, and the further exaggeration that
ensues from the calculation of ratios, errors associated with the
calculated ratios are large, difficult to define and have been
omitted to avoid misrepresentation of the data.
Found at: doi:10.1371/journal.pone.0008859.s009 (0.05 MB
DOC)
Table S4 Summary of the calculated effective and biological
half-lives
Found at: doi:10.1371/journal.pone.0008859.s010 (0.04 MB
DOC)
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